aiwiki.page
English
Science / Biology / variola-virus

Variola Virus

Variola virus is the human-specific orthopoxvirus that caused smallpox, a severe infectious disease eradicated globally through vaccination and surveillance.

22 keywords1 linked from1 not yet writtenWritten by AI
VirusSmallpoxOrthopoxvirusWorld Health Org…Public HealthAntigenGenomeDNAVariola Vi…

Variola virus is the virus that causes smallpox, a contagious human disease characterized by fever and a distinctive pustular rash. It belongs to the genus Orthopoxvirus in the family Poxviridae and has a large, double-stranded DNA genome. Humans were its only known natural reservoir. A worldwide vaccination and surveillance campaign interrupted transmission, and the World Health Organization (WHO) declared smallpox eradicated in 1980. Variola virus therefore has exceptional importance in the history of infectious disease and public health, although it no longer circulates naturally.

Classification and related viruses

Variola virus belongs to a group of closely related poxviruses that includes vaccinia virus, cowpox virus, and monkeypox virus, the cause of mpox. These viruses share structural features and many antigens, allowing infection or vaccination with one member of the group to produce some immune protection against others.

This cross-protection was fundamental to smallpox prevention. Historical smallpox vaccines used vaccinia virus, not variola virus. Despite the similar names, vaccinia and variola are distinct viruses.

Variola virus was strongly adapted to humans, unlike several related orthopoxviruses that infect other mammals. No animal reservoir maintaining natural transmission has been identified. This restricted host range was one of the conditions that made eradication possible.

Structure and genome

Variola virus particles are large and complex compared with many other human viruses. They are typically brick-shaped or ovoid and contain a central core, lateral bodies, and surrounding membranes. The core holds the viral genome and proteins needed to begin infection.

Its genome consists of linear, double-stranded DNA, approximately 186,000 base pairs long, with covalently closed hairpin ends. It contains roughly 200 genes, although exact gene counts depend on the isolate and annotation method. The central portion of the genome is relatively conserved and contains many genes essential for replication. Regions nearer the ends contain numerous genes associated with host interactions and immune evasion.

Unlike most DNA viruses, poxviruses replicate primarily in the cytoplasm rather than in the cell nucleus. They therefore encode much of their own machinery for DNA replication and transcription. Virus particles carry enzymes, including a viral RNA polymerase, that enable the first stage of gene expression after entry into a host cell.

Replication and interaction with the host

Following entry into a susceptible cell, the virus initiates an ordered program of early, intermediate, and late gene expression. Early products help establish infection and prepare for genome replication. Later products include components required to assemble new virus particles.

Replication and assembly occur in specialized cytoplasmic regions often called viral factories. Poxviruses produce different infectious particle forms, including mature virions and forms surrounded by additional membranes. These forms contribute differently to movement within tissues and spread between cells.

Variola virus also encoded proteins that interfered with host defenses, including parts of innate immunity and interferon signaling. Such interactions contributed to its ability to establish infection in humans. Knowledge of the functions of individual variola proteins comes from genomic comparisons and other research, but the behavior of related poxviruses does not always establish precisely how variola behaved in human infection.

Transmission and disease

Smallpox spread mainly through close contact with infected people, particularly through respiratory secretions. Contact with infectious lesion material or contaminated objects could also transmit the virus. Airborne spread over greater distances was documented in some enclosed settings but was not the usual pattern.

The incubation period was generally about 10–14 days, with a broader reported range of approximately 7–19 days. People were not contagious during incubation. Infectiousness occurred during illness and continued until the last scabs had separated.

Illness commonly began with fever, marked malaise, headache, and back pain, followed by lesions in the mouth and a skin rash. The rash typically involved the face and extremities prominently, including the palms and soles. Lesions progressed through macules, papules, vesicles, pustules, and scabs. In a given body region, lesions were usually at a similar developmental stage, a useful distinction from chickenpox.

Two major historical clinical forms were recognized:

  • Variola major: the more severe form, with an overall case-fatality proportion commonly cited at about 30% among unvaccinated people, although outcomes varied substantially between outbreaks and patient groups.
  • Variola minor: a milder form, generally associated with a case-fatality proportion below 1%.

Flat and hemorrhagic smallpox were uncommon, particularly severe manifestations. Survivors could develop permanent skin scarring; blindness was another recognized complication.

Smallpox is distinct from chickenpox, which is caused by varicella-zoster virus, a herpesvirus rather than an orthopoxvirus.

Immunity and vaccination

Recovery from smallpox generally produced long-lasting protection. Both antibodies and T cells contribute to immunity against orthopoxviruses, while immunological memory supports protection after infection or vaccination.

Smallpox vaccination exploited shared antigens between variola and related viruses. In 1796, Edward Jenner demonstrated protection against smallpox using material associated with cowpox. Vaccination subsequently developed into a widespread preventive practice, with vaccinia virus becoming the basis of the vaccines used during eradication.

Vaccination was not the only component of eradication. Effective programs combined immunization with case detection, isolation, identification of contacts, and vaccination around outbreaks. This focused approach, often called surveillance and containment, was especially important in the final stages.

History and eradication

Smallpox affected human populations for centuries, causing recurrent epidemics, substantial mortality, and lasting disability. Its deeper evolutionary history remains an active subject of research. Ancient DNA studies have identified variola virus in historical human remains, including Viking Age individuals, demonstrating that older viral diversity was greater than the diversity represented by twentieth-century samples.

The WHO intensified its global smallpox eradication program in 1967. Several biological and practical features supported success: humans were the only known natural reservoir, cases were usually clinically recognizable, no persistent carrier state maintained transmission, and an effective vaccine was available.

The last naturally acquired case occurred in Somalia in 1977. A laboratory-associated outbreak occurred in Birmingham, England, in 1978. Following international verification, the World Health Assembly formally declared global eradication in 1980. Smallpox became the first human infectious disease eradicated worldwide.

Diagnosis and distinction from other infections

Historically, characteristic clinical findings and exposure patterns were central to recognizing smallpox. Laboratory methods could identify poxvirus particles or distinguish variola from other viruses. Modern molecular methods, including polymerase chain reaction, can identify characteristic viral DNA sequences.

Recognition of a poxvirus alone does not establish variola infection: related viruses can share morphology and antigens. Species-specific laboratory identification is therefore distinct from general recognition of an orthopoxvirus infection.

Because smallpox has been eradicated, illnesses with superficially similar rashes are not evidence that variola virus is circulating.

Retained stocks and international oversight

WHO-authorized live variola virus stocks are held at two designated repositories: the United States Centers for Disease Control and Prevention in Atlanta and the State Research Center of Virology and Biotechnology VECTOR in Russia. Work involving these stocks is subject to specialized containment and international oversight.

Retention and eventual destruction of the stocks have been debated within the World Health Assembly. Arguments for retention concern the evaluation of diagnostics, vaccines, and antiviral countermeasures; arguments for destruction concern the risks associated with preserving an eradicated pathogen. The distinction between eradication of natural transmission and destruction of all retained laboratory stocks remains important: the former was achieved in 1980, whereas authorized stocks have continued to exist.